Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q1 2025 · 10-Q
Revenue$375.00K$375.00K+32.0% vs Q1 2024 Net Income-$19.34M-$19.34MN/M vs Q1 2024 EPS Diluted-$0.01-$0.01N/M vs Q1 2024 Operating Income-$17,311,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
Free Cash Flowderived-$9,511,000N/M Margins · derivedOperating margin-4616.3%+927.4 pt vs Q1 2024
Net margin-5158.1%+1289.8 pt vs Q1 2024
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end